摘要
目的 比较吡仑帕奈(Perampanel,PER)和奥卡西平(Oxcarbazepine,OXC)单药治疗成入新诊断局灶性癫痫的有效性和安全性.方法 纳入清远市人民医院2021年8月-2022年10月新诊断的62例成人局灶性癫痫患者,年龄18～79岁,平均(40.53±16.69)岁,随机分为PER组和OXC组.两组均随访12个月,并分析第3、6、12个月的癫痫无发作率、有效率、药物保留率,以及两组的不良反应情况.结果 PER组32例,OXC组30例.3个月时PER组癫痫无发作率62.5％、有效率71.9％、药物保留率87.5％;OXC组癫痫无发作率70.0％、有效率86.7％、药物保留率93.3％.6个月时PER组癫痫无发作率53.1％、有效率65.6％、保留率75.0％;OXC组癫痫无发作率66.7％、有效率73.3％、保留率83.3％.12个月时PER组癫痫无发作率43.8％、有效率46.9％、保留率53.1％;OXC组癫痫无发作率66.7％、有效率66.7％、保留率70.0％.PER组与OXC组不良反应发生率分别为15.6％和16.7％,两组最常见的不良反应均为头晕和嗜睡,无严重不良事件.结论 PER和OXC在新诊断的成人局灶性癫痫中具有相似的疗效及安全性,两种药物均可作为成人局灶性癫痫的安全有效的治疗选择.
Abstract
Objective To compare the efficacy and safety of perampanel(PER)and oxcarbazepine(OXC)monotherapy in the treatment of newly diagnosed focal epilepsy in adults.Methods A total of 62 adult patients with focal epilepsy,aged 18～79 years old,with an average age of(40.53±16.69)years,were enrolled from Qingyuan People's Hospital between August 2021 and October 2022 and randomly divided into PER group and OXC groups.Both groups were followed up for 12 months and assessed for seizure free rate,effective rate,drug retention rate,and adverse reactions at 3,6,and 12th months.Results The results showed that the seizure free rate,effective rate,and drug retention rate in the PER group were 62.5％,71.9％and 87.5％at 3 months,respectively,and 53.1％,65.6％and 75.0％at 6 months respectively.In the OXC group,the seizure free rate,effective rate,and drug retention rate were 70.0％,86.7％,and 93.3％at 3 months,respectively,and 66.7％,73.3％and 83.3％at 6 months,respectively.At 12 months,the seizure free rate,effective rate and retention rate of the PER group were 43.8％,46.9％,and 53.1％,respectively;The seizure free rate,effective rate,and retention rate of OXC group were 66.7％,66.7％,and 70.0％,respectively.The incidence of adverse reactions in the PER group and OXC group was 15.6％and 16.7％,respectively.The most common adverse reactions in both groups were dizziness and drowsiness,with no serious adverse events.Conclusion PER and OXC monotherapy demonstrated similar efficacy and safety in the treatment of newly diagnosed adult focal epilepsy,and both drugs can be used as safe and effective treatment options.
NETL
NSTL
维普
万方数据